Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension

Journal of Hypertension

Volumn 16, Issue 6, 1998, Pages 835-841

  Massart, Pierre Emmanuel ^a   Hodeige, Dominique G ^a   Van Mechelen, Henri ^a   Charlier, André A ^a   Ketelslegers, Jean Marie ^a   Heyndrickx, Guy R ^b   Donckier, Julian E ^c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CARDIOVASCULAR CENTER   (Belgium)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

Angiotensin ii receptor antagonist; Dogs; Endothelin receptor antagonist; Endothelin 1; Page hypertension

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; LOSARTAN;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; AORTA PRESSURE; ARTICLE; CONTROLLED STUDY; DOG; HEART LEFT VENTRICLE PRESSURE; HEART RATE; HORMONE BLOOD LEVEL; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE;

EID: 0031836657     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816060-00015     Document Type: Article

References (33)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayaski M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
2. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988; 238:249-251.
3. Donckier J, Hanet C, Berbinschi A, Galanti L, Robert A, Van Mechelen H, et al. Cardiovascular and endocrine effects of endothelin-1 at pathophysiological and pharmacological plasma concentrations in conscious dogs. Circulation 1991; 84:2476-2484.
4. Schiffrin E, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens 1991; 4:303-308.
5. Suzuki N, Miyauchi T, Tomobe Y, Matsumoto H, Goto K, Masaki T, et al. Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats. Biochem Biophys Res Commun 1990; 30:941-947.
6. Donckier J, Stoleru L, Hayashida W, Van Mechelen H, Selvais P, Galanti L, et al. Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation 1995; 92:106-113.
7. Kohno M, Murakawa K, Horio T, Yokokawa K, Yasunari K, Fukui T. Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension 1991; 18:93-100.
8. Kohno M, Yasunari K, Murakawa K, Yokokawa K, Horio T, Fukui T, et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990; 88:614-618.
9. Lariviere R, Thibault G, Schiffrin E. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993; 21: 294-300.
10. Zeiher A, Ihling C, Pistorius K, Schachinger V, Schaefer H. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994; 344:1405-1406.
11. Schiffrin E, Lariviere R, Li J, Sventek P, Touyz R. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995; 25:769-773.
12. Lariviere R, Deng L, Day R, Sventek P, Thibault G, Schiffrin E. Increased endothelin-1 gene expression in the endothelium of coronary arteries and endocardium in the DOCA-salt hypertensive rat. J Mol Cell Cardiol 1995; 27:2123-2131.
13. Wagner O, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny P, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267:16066-16068.
14. Douglas S, Gellai M, Ezekiel M, Ohlstein E. BO-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens 1994; 12:561-567.
15. Masaki T. Endothelins: homeostatic and compensatory actions in the circulatory and endocrine systems. Endocr Rev 1993; 14:256-268.
16. Donckier J, Massart PE, Hodeige D, Van Mechelen H, Clozen JP, Heyndrickx G, et al. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin converting enzyme inhibition. Circulation 1997; 96:1250-1256.
17. Kohno M, Horio T, Ikeda M, Yokokana K, Fukui T, Yasunari K, et al. Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int 1992; 42:860-866.
18. Kohno M, Yasunari K, Yokokawa K, Murakawa K, Horio T, Takeda T. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured hormone endothelial cells. J Clin Invest 1991; 87:1999-2004.
19. Urata H, Healy B, Stewart RW, Bumpus M, Husain A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res 1990; 66:883-890.
20. Page IH. The production of persistent arterial hypertension by cellophane perinephritis. JAMA 1939; 113:2046-2048.
21. Sansdrap J, Van Mechelen H, Pouleur H, Charlier A. CROPA: a research-oriented program for automatic processing of cardiovascular signals. In: Computers in cardiology. Florence: IEEE Computers Society; 1981. pp. 433-436.
22. Beyer M, Slesak G, Hoffmeister H. In vivo hemodynamic and inotropic effects of the endothelin B agonist IRL 1620. J Cardiovasc Pharmacol 1995; 26:S190-S192.
23. Beyer M, Slesak G, Nerz S, Kazmaier S, Hoffmeister H. Effects of endothelin-1 and IRL 1620 on myocardial energy metabolism. J Cardiovasc Pharmacol 1995; 26:S150-S152.
24. Shimoyama H, Sabbah N, Borzak S, Tanimura M, Shevlyagin S, Scicli G, et al. Short term hemodyamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation 1996; 94:779-784.
25. B endothelin-1 receptor antagonist) preserves heart function in hypertensive dogs [abstract]. Eur J Clin Invest 1996; 26:33.
26. Hayashida W, Donckier J, Van Mechelen H, Charlier AA, Pouleur H. Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin type-1 receptor blockade. Cardiovasc Res 1997; 33:54-62.
27. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346:732-736.
28. A-receptor antagonist. Circulation 1997; 96:1593-1597.
29. Dupuis J, Goresky C, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996; 81:1510-1515.
30. Hemsen A, Modin A, Wanecek M, Malmstrom RE, Weitzberg E. Effects of RO 0203 and PD155080 on the plasma kinetics, receptor binding and vascular effects of endothelin in the pig. Eur J Pharmacol 1996; 318:369-376.
31. Schiffrin E, Turgeon A, Deng L. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br J Pharmacol 1997; 121:935-940.
32. Li J, Lariviere R, Schiffrin E. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 994; 24:183-188.
33. Li J, Schiffrin E. Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. J Hypertens 1995; 13:647-652.